MedTrace Logo

Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure

NCT05261321 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-03

No results posted yet for this study

Summary

The purpose of this Phase I non-therapeutic trial is to examine the neurological effects of cannabis on stress reactivity and inhibition in healthy cannabis users. We expect differences between high ratio CBD:THC cannabis oil, low ratio CBD:THC cannabis oil, and/or placebo on outcome measures.

Conditions

  • Healthy

Interventions

DRUG

Cannabis oil with a high ratio of THC to CBD

In the first active condition, cannabis oil with a high THC to CBD ratio will be administered to participants.

DRUG

Cannabis oil with a high ratio of CBD to THC

In the second active condition, cannabis oil with a high CBD to THC ratio will be administered to participants.

DRUG

Placebo

In the control condition, the placebo will be administered to participants.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Christian G Schütz, MD PhD · University of British Columbia; British Columbia Mental Health and Substance Use Services

  • Karina A Thiessen, BA BEd · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-15
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05261321 on ClinicalTrials.gov